EGFR and adenocarcinoma: Consistent with previous studies in first line, patients who were Asian (HR 0.40, 95% CI 0.21–0.58), female (HR 0.61, 95% CI 0.46–0.75), non-smoker (HR 0.53, 95% CI 0.31–0.75), those who had adenocarcinoma (HR 0.59, 95% CI 0.38–0.79) and most impressively, EGFR mutant (HR 0.12, 95% CI 0.03–0.21) may benefit more from EGFR TKIs.